A Phase II Study of Bulk Versus Fractionated Stem Cell Infusions in Patients with Hematologic Cancers Undergoing Stem Cell Transplantation

Full Title

Randomized Phase II Trial of Bulk Versus Fractionated Stem Cell Infusions in Patients with Hematologic Malignancies Undergoing Stem Cell Transplantation


Stem cell transplantation — giving stem cells from a donor to a patient — is a means of treating certain hematologic cancers (such as leukemia, lymphoma, and multiple myeloma). The purpose of this study is to see if giving donor stem cells over several days helps the blood and immune systems recover more quickly than when stem cells are given all in one day (the conventional approach). Laboratory studies have suggested that recovery of the blood and immune systems may be faster when stem cells are infused over several days.

Patients in this study will be randomly assigned to receive stem cells in one day or over four days.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must be candidates for stem cell transplantation as treatment for acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome or other myeloproliferative disorders, non-Hodgkin lymphoma, Hodgkin lymphoma, or multiple myeloma.
  • Patients must have a matched donor of stem cells.
  • Patients must be under age 75.

For more information about this study and to inquire about eligibility, please contact Dr. Sergio Giralt at 212-639-6009.